Eloxx Pharmaceuticals to Present at the Evercore ISI 2nd Annual HealthCONx on December 4th, 2019
November 19 2019 - 7:00AM
Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage
biopharmaceutical company dedicated to the discovery and
development of novel therapeutics to treat cystic fibrosis,
cystinosis, inherited retinal disorders and other diseases caused
by nonsense mutations limiting production of functional proteins,
today announced that Robert E. Ward, Chairman and Chief Executive
Officer of Eloxx, will participate in a fireside chat and host
one-on-one meetings with investors at the
Evercore ISI 2nd
Annual HealthCONx on December 4th, 2019 at the Boston Four
Seasons Hotel.
The presentation will be webcast live and may be
accessed by visiting the “Events & Presentations” page within
the Investors section of the Eloxx website at
http://investors.eloxxpharma.com or by using the link below. A
replay of the webcast will be available on the Eloxx website
following the conference.
Date: Wednesday, December 4,
2019Time: 4:15 P.M. ETWebcast:
http://wsw.com/webcast/evercore4/elox
About Eloxx
PharmaceuticalsEloxx Pharmaceuticals, Inc. is a
clinical-stage biopharmaceutical company developing novel
RNA-modulating drug candidates (designed to be eukaryotic ribosomal
selective glycosides) that are formulated to treat rare and
ultra-rare premature stop codon diseases. Premature stop codons are
point mutations that disrupt protein synthesis from messenger RNA.
As a consequence, patients with premature stop codon diseases have
reduced or eliminated protein production from the mutation bearing
allele accounting for some of the most severe phenotypes in these
genetic diseases. These premature stop codons have been identified
in over 1,800 rare and ultra-rare diseases.
Read-through therapeutic development is focused on extending
mRNA half-life and increasing protein synthesis by enabling the
cytoplasmic ribosome to read through premature stop codons to
produce full-length proteins. Eloxx’s lead investigational product
candidate, ELX-02, is a small molecule drug candidate designed to
restore production of full-length functional proteins. ELX-02 is in
the early stages of clinical development focusing on cystic
fibrosis and cystinosis. ELX-02 is an investigational drug that has
not been approved by any global regulatory body. Eloxx’s
preclinical candidate pool consists of a library of novel drug
candidates designed to be eukaryotic ribosomal selective glycosides
identified based on read-through potential. Eloxx recently
announced a new program focused on rare ocular genetic disorders.
Eloxx is headquartered in Waltham, MA, with operations in Rehovot,
Israel. For more information, please visit www.eloxxpharma.com.
Forward-Looking Statements
This press release contains forward-looking statements, which
are generally statements that are not historical facts.
Forward-looking statements can be identified by the words
“expects,” “anticipates,” “believes,” “intends,” “estimates,”
“plans,” “will,” “outlook” and similar expressions. Forward-looking
statements are based on management's current plans, estimates,
assumptions and projections, and speak only as of the date they are
made. We undertake no obligation to update any forward-looking
statement in light of new information or future events, except as
otherwise required by law. Forward-looking statements involve
inherent risks and uncertainties, most of which are difficult to
predict and are generally beyond our control. Actual results or
outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, including: the development of the Company’s read-through
technology; the approval of the Company’s patent applications; the
Company’s ability to successfully defend its intellectual property
or obtain necessary licenses at a cost acceptable to the Company,
if at all; the successful implementation of the Company’s research
and development programs and collaborations; the Company’s ability
to obtain applicable regulatory approvals for its current and
future product candidates; the acceptance by the market of the
Company’s products should they receive regulatory approval; the
timing and success of the Company’s preliminary studies,
preclinical research, clinical trials, and related regulatory
filings; the ability of the Company to consummate additional
financings as needed; as well as those discussed in more detail in
our Annual Report on Form 10-K and our other reports filed with
the Securities and Exchange Commission.
Contact:
Barbara Ryan203-274-2825barbarar@eloxxpharma.com
SOURCE: Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eloxx Pharmaceuticals (NASDAQ:ELOX)
Historical Stock Chart
From Apr 2023 to Apr 2024